Cytochrome P 450 and Glutathione Transferase Expression in Squamous Cell Cancer
Shadan Ali,B. El-Rayes,L. Heilbrun,F. Sarkar,J. Ensley,O. Kucuk,P. Philip
Abstract:Purpose: The cytochrome P-450 (CYP) and glutathione S-transferase (GST) enzyme systems modulate the carcinogenic effects of tobacco. Therefore, the expression of these enzymes may be in part responsible for the observed interindividual and inter-racial differences in the risk of development of squamous cell carcinoma of the head and neck (SCCHN). The first aim of this study was to evaluate the feasibility of measuring the expression of the CYP and GST in target tissue from the head and neck. The second aim was to compare the expression of CYPs 1A1, 2E1, and 3A4 in squamous epithelium from African-American and Caucasian pediatric patients. The third aim was to compare the expression of CYPs 1A1, 2E1, 3A4, and GSTon the p16 expression in patients with SCCHN. Experimental Design: The expression of CYP 1A1, 2E1, 3A4, GST, and p16 was quantified by immunoblotting. Expression of CYPs 1A1, 2E1, and 3A4 was quantified in tissue from 160 pediatric patients undergoing tonsillectomy. Expression of CYPs 1A1, 2E1, 3A4, GST, and p16 was determined in 46 resected SCCHN patients. Results: Large interindividual variability in the expression of these enzymes was observed in the pediatric and adult populations. No significant difference was observed in CYP 1A1, 2E1, and 3A4 expression of Caucasian and African-American patients. There was no correlation between p16 and enzyme expression in patients with SCCHN. Conclusion: Evaluation of CYP expression in the target tissue of interest is feasible. The clinical significance of CYPs and GSTalterations in the risk of developing SCCHN will need to be investigated in larger trials. INTRODUCTION Tobacco exposure is an established risk factor for several cancers including squamous cell cancer of the head and neck (SCCHN; Ref. 1). The development of tobacco related malignancies appears to depend on the duration and intensity of exposure to the carcinogen (2) as well as genetic susceptibility (1, 2). The presence of genetic susceptibilities is confirmed by the higher incidence of cancer in first-degree relatives of patients with SCCHN (3) and the inter-racial differences in the susceptibility to the carcinogenic effects of tobacco (4). Understanding the mechanisms of susceptibility will facilitate the prevention and early detection of SCCHN. The carcinogen metabolizing enzymes are involved in the activation and deactivation of diverse chemical carcinogens. Interindividual and inter-racial variations in the expression of these enzymes in target tissues may explain the different susceptibilities observed in clinical and epidemiological studies (5). Cytochrome P450 (CYP) is a superfamily of heme-containing mono-oxygenases that is involved in the metabolism of a wide variety of endogenous and exogenous compounds (6). Enzymes of the CYP family may have different but overlapping substrate specificities (Table 1; Refs. 6, 7). The regulation of CYP expression is in part tissue-specific (8). Marked enzymatic activities of CYPs 1A1, 2E1, and 3A4 have been demonstrated in the human head and neck squamous epithelium (9). Glutathione S-transferases (GSTs) are involved in the Phase II metabolism that generally detoxifies carcinogens. GSThas been shown to be expressed in the human squamous epithelium (10). Carcinogens and their metabolites result in malignant transformation through mutations altering the function of critical proto-oncogenes or tumor suppressor genes. The inactivation of the p16 gene is an early event in the development of SCCHN that occurs in up to 80% of patients (11). Therefore, the p16 expression may be used as a surrogate for the carcinogenic effects of tobacco in SCCHN. The aim of this study was to evaluate the effects of the expression of CYP and GSTenzymes on the development of SCCHN. We hypothesized that the expression of the CYPs 1A1, 3A4, and 2E1 would be higher in normal tissue from nonsmokers of African-American descent as compared with Caucasians. This might explain the observed increased susceptibility to the carcinogenic effects of tobacco in African Americans. The second hypothesis was that the expression of CYPs would be lower in the SCCHN tissue as compared with the normal adjacent tissue. The third hypothesis was that a higher expression of CYPs 1A1, 3A4, and 2E1 in normal tissue from patients with SCCHN would be associated with a lower p16 expression in the tumor tissue, and that a higher expression of GSTin normal tissue from patients with SCCHN would be associated with a higher p16 expression. Received 1/23/04; revised 3/15/04; accepted 4/1/04. Grant support: NIH Cancer Center Support Grant CA-22453. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Requests for reprints: Philip A. Philip, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201. Phone: (313) 745-9155; Fax: (313) 9662944; E-mail: philipp@karmanos.org. 4412 Vol. 10, 4412–4416, July 1, 2004 Clinical Cancer Research Research. on June 2, 2017. © 2004 American Association for Cancer clincancerres.aacrjournals.org Downloaded from MATERIALS AND METHODS Study Population. Pediatric patients undergoing tonsillectomy and adult patients with SCCHN undergoing surgical excision were eligible for this study. All of the patients provided a signed informed consent in accordance with the Wayne State University Human Investigation Committee guidelines before enrolment on the study. Tissue Collection. The pathological material was obtained fresh at time of surgery. The pathologist histologically examined tissue from patients with SCCHN. Tumor samples were obtained from unequivocal sites within the specimen. Normal tissue samples were obtained from morphologically normal adjacent tissue that was at least 1 cm away from the cancer site. All of the samples were covered with aluminum foil, sealed in plastic bags, coded, and stored at 70°C until analysis. Assays were done in batches of 10–20 samples and without knowledge of the sample source. Western Blot Analysis (Immunoblotting). The minimum tissue weights sufficient for all of the intended analyses were 200 mg. Tissue samples were suspended in 2 ml of homogenizing buffer (pH 7.4) containing 50 mM Tris, 0.25 M sucrose, and 1 mM EDTA. The samples were then homogenized twice followed by centrifugation at 12,000 rpm for 30 min at 4°C. The supernatant was centrifuged at 45,000 rpm for 1 h at 4°C. The microsome pellet was suspended by sonication in 25 l of microsomal storage buffer (50 mM Tris, 20% glycerol, and 1 mM EDTA). The concentration of proteins was determined by bicinchonic acid assay using spectrophotometer and measured at an absorbance of 562 nm. Approximately 20 g of protein from each sample were loaded onto a 10% SDS-polyacrylamide gel along with three different concentrations of each of the known enzyme standards. Gels were run at 120 V for 90 min and subsequently transferred onto a nitrocellulose membrane. The membrane was blocked for 1 h at room temperature by PBS/0.05 Tween 20 containing 5% powdered milk. It was then treated with the primary antibody 3A4, 1A1, or 2E1 (Gentest Corporation, Woburn, MA), GST(Oxford Biomedicals, Rochester Hills, MI), or p16 (Santa Cruz Biotechnology, Santa Cruz, CA) to the enzymes using optimized dilutions. Membranes were washed and treated with a secondary antibody (horseradish peroxidase conjugate). Protein bands were detected by enhanced chemiluminescent substrate. -Actin expression was used to standardize the loading of the protein sample. The intensity of the protein band was quantified by an image analysis system (Storm System; Molecular Dynamics, (Piscataway, NJ). The intensity of the bands from the patient samples was determined from the standard linear curve encompassing the actual experimental measurements and corrected for the expression of -actin in each sample. Enzyme levels were expressed in relative arbitrary units. Statistical Methods. The enzyme distributions were highly skewed and non-normal, so nonparametric methods of analysis were used (12). Comparisons of enzyme levels between subgroups of patients were performed using the Kruskal-Wallis rank sum test (for three groups) or the Wilcoxon rank sum test (for two groups). The strength of association between enzymes was assessed via a Spearman’s rank correlation. To control overall type I error, adjustment for multiple comparisons was performed using the Holm method (13).